{'fraction_non_alphanumeric': 0.027246653919694074, 'fraction_numerical': 0.0248565965583174, 'mean_word_length': 4.781767955801105, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
FA04.06: RESECTION OF HEPATIC AND PULMONARY METASTASIS FROM ESOPHAGEAL AND GASTRIC CANCER: A NATIONWIDE STUDY


 
 
 Best supportive care or palliative chemotherapy is the standard of care for gastroesophageal cancer patients with hepatic or pulmonary metastases, leading to a median survival of 4–11 months. Occasionally, patients with oligometastatic disease may be eligible for curative treatment. The aim of the current study was to evaluate the outcomes of all patients in the Netherlands who underwent a resection of hepatic or pulmonary metastases with curative intent for metastatic gastroesophageal cancer.
 
 
 
 The Dutch National Registry for Histo- and Cytopathology was used to identify all patients who underwent a resection of hepatic or pulmonary metastasis from gastroesophageal cancer. Patients who were treated with curative intent and had available patient records were included. Data on treatment and outcomes were retrieved from the patient's record. Kaplan-Meier survival analysis was performed.
 
 
 
 The primary tumor of 34 patients with gastroesophageal cancer was resected in 21 different hospitals between 1991–2016. Additionally, resection of hepatic metastasis was performed in 19 patients and of pulmonary metastasis in 15 patients. Only 4 patients received neoadjuvant therapy before metastasectomy. The majority of patients had solitary, metachronous metastases. After metastasectomy, grade 3 (Clavien-Dindo) complications occurred in 7 patients and mortality in 1 patient. After resection of hepatic metastases, the median overall survival (OS) was 28 months and the 1-, 3- and 5- year OS were 84%, 41% and 31% respectively. After pulmonary metastases resection, the median OS was not reached and the 1-, 3- and 5- year OS were 67%, 53% and 53% respectively.
 
 
 
 In selected patients with gastroesophageal cancer with hepatic or pulmonary metastases, metastasectomy was performed with limited morbidity and mortality and offered a 5-year OS of 31–53%. Further prospective studies are required.
 
 
 
 All authors have declared no conflicts of interest.
